

Rare Hematology Treatment Market - Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/R5176197AA77EN.html>

Date: March 2022

Pages: 65

Price: US\$ 3,250.00 (Single User License)

ID: R5176197AA77EN

Abstracts

Growing prevalence of various blood diseases such as anemia, myeloma, leukemia and sickle cell anemia has led the hematologists to focus on various detection processes. As demand for comparatively conducting comparatively short diagnosis process is becoming the need of the hour, hematologists are looking for better treatment processes through accurate diagnosis process.

This report contains market size and forecasts of Rare Hematology Treatment in Global, including the following market information:

Global Rare Hematology Treatment Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Rare Hematology Treatment market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Plasma Derived Factors Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Rare Hematology Treatment include Takeda, Biogen, Novo Nordisk, Bayer, CSL Behring, Pfizer, PRA Health Sciences, Celgene and Alexion Pharma and etc. In 2021, the global top five players have a share approximately % in

terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Rare Hematology Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Rare Hematology Treatment Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Rare Hematology Treatment Market Segment Percentages, by Type, 2021 (%)

Plasma Derived Factors

Recombinant Factors

Global Rare Hematology Treatment Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Rare Hematology Treatment Market Segment Percentages, by Application, 2021 (%)

Hemophilia A

Hemophilia B

Von Willebrand Disease

Others

Global Rare Hematology Treatment Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global Rare Hematology Treatment Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Rare Hematology Treatment revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Rare Hematology Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Takeda

Biogen

Novo Nordisk

Bayer

CSL Behring

Pfizer

PRA Health Sciences

Celgene

Alexion Pharma

Amgen

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Rare Hematology Treatment Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Rare Hematology Treatment Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL RARE HEMATOLOGY TREATMENT OVERALL MARKET SIZE

- 2.1 Global Rare Hematology Treatment Market Size: 2021 VS 2028
- 2.2 Global Rare Hematology Treatment Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Rare Hematology Treatment Players in Global Market
- 3.2 Top Global Rare Hematology Treatment Companies Ranked by Revenue
- 3.3 Global Rare Hematology Treatment Revenue by Companies
- 3.4 Top 3 and Top 5 Rare Hematology Treatment Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Rare Hematology Treatment Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Rare Hematology Treatment Players in Global Market
 - 3.6.1 List of Global Tier 1 Rare Hematology Treatment Companies
 - 3.6.2 List of Global Tier 2 and Tier 3 Rare Hematology Treatment Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Rare Hematology Treatment Market Size Markets, 2021 & 2028

4.1.2 Plasma Derived Factors

4.1.3 Recombinant Factors

4.2 By Type - Global Rare Hematology Treatment Revenue & Forecasts

4.2.1 By Type - Global Rare Hematology Treatment Revenue, 2017-2022

4.2.2 By Type - Global Rare Hematology Treatment Revenue, 2023-2028

4.2.3 By Type - Global Rare Hematology Treatment Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Rare Hematology Treatment Market Size, 2021 & 2028

5.1.2 Hemophilia A

5.1.3 Hemophilia B

5.1.4 Von Willebrand Disease

5.1.5 Others

5.2 By Application - Global Rare Hematology Treatment Revenue & Forecasts

5.2.1 By Application - Global Rare Hematology Treatment Revenue, 2017-2022

5.2.2 By Application - Global Rare Hematology Treatment Revenue, 2023-2028

5.2.3 By Application - Global Rare Hematology Treatment Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Rare Hematology Treatment Market Size, 2021 & 2028

6.2 By Region - Global Rare Hematology Treatment Revenue & Forecasts

6.2.1 By Region - Global Rare Hematology Treatment Revenue, 2017-2022

6.2.2 By Region - Global Rare Hematology Treatment Revenue, 2023-2028

6.2.3 By Region - Global Rare Hematology Treatment Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Rare Hematology Treatment Revenue, 2017-2028

6.3.2 US Rare Hematology Treatment Market Size, 2017-2028

6.3.3 Canada Rare Hematology Treatment Market Size, 2017-2028

6.3.4 Mexico Rare Hematology Treatment Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Rare Hematology Treatment Revenue, 2017-2028

- 6.4.2 Germany Rare Hematology Treatment Market Size, 2017-2028
- 6.4.3 France Rare Hematology Treatment Market Size, 2017-2028
- 6.4.4 U.K. Rare Hematology Treatment Market Size, 2017-2028
- 6.4.5 Italy Rare Hematology Treatment Market Size, 2017-2028
- 6.4.6 Russia Rare Hematology Treatment Market Size, 2017-2028
- 6.4.7 Nordic Countries Rare Hematology Treatment Market Size, 2017-2028
- 6.4.8 Benelux Rare Hematology Treatment Market Size, 2017-2028

6.5 Asia

- 6.5.1 By Region - Asia Rare Hematology Treatment Revenue, 2017-2028
- 6.5.2 China Rare Hematology Treatment Market Size, 2017-2028
- 6.5.3 Japan Rare Hematology Treatment Market Size, 2017-2028
- 6.5.4 South Korea Rare Hematology Treatment Market Size, 2017-2028
- 6.5.5 Southeast Asia Rare Hematology Treatment Market Size, 2017-2028
- 6.5.6 India Rare Hematology Treatment Market Size, 2017-2028

6.6 South America

- 6.6.1 By Country - South America Rare Hematology Treatment Revenue, 2017-2028
- 6.6.2 Brazil Rare Hematology Treatment Market Size, 2017-2028
- 6.6.3 Argentina Rare Hematology Treatment Market Size, 2017-2028

6.7 Middle East & Africa

- 6.7.1 By Country - Middle East & Africa Rare Hematology Treatment Revenue, 2017-2028
- 6.7.2 Turkey Rare Hematology Treatment Market Size, 2017-2028
- 6.7.3 Israel Rare Hematology Treatment Market Size, 2017-2028
- 6.7.4 Saudi Arabia Rare Hematology Treatment Market Size, 2017-2028
- 6.7.5 UAE Rare Hematology Treatment Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Takeda

- 7.1.1 Takeda Corporate Summary
- 7.1.2 Takeda Business Overview
- 7.1.3 Takeda Rare Hematology Treatment Major Product Offerings
- 7.1.4 Takeda Rare Hematology Treatment Revenue in Global Market (2017-2022)
- 7.1.5 Takeda Key News

7.2 Biogen

- 7.2.1 Biogen Corporate Summary
- 7.2.2 Biogen Business Overview
- 7.2.3 Biogen Rare Hematology Treatment Major Product Offerings
- 7.2.4 Biogen Rare Hematology Treatment Revenue in Global Market (2017-2022)

7.2.5 Biogen Key News

7.3 Novo Nordisk

7.3.1 Novo Nordisk Corporate Summary

7.3.2 Novo Nordisk Business Overview

7.3.3 Novo Nordisk Rare Hematology Treatment Major Product Offerings

7.3.4 Novo Nordisk Rare Hematology Treatment Revenue in Global Market (2017-2022)

7.3.5 Novo Nordisk Key News

7.4 Bayer

7.4.1 Bayer Corporate Summary

7.4.2 Bayer Business Overview

7.4.3 Bayer Rare Hematology Treatment Major Product Offerings

7.4.4 Bayer Rare Hematology Treatment Revenue in Global Market (2017-2022)

7.4.5 Bayer Key News

7.5 CSL Behring

7.5.1 CSL Behring Corporate Summary

7.5.2 CSL Behring Business Overview

7.5.3 CSL Behring Rare Hematology Treatment Major Product Offerings

7.5.4 CSL Behring Rare Hematology Treatment Revenue in Global Market (2017-2022)

7.5.5 CSL Behring Key News

7.6 Pfizer

7.6.1 Pfizer Corporate Summary

7.6.2 Pfizer Business Overview

7.6.3 Pfizer Rare Hematology Treatment Major Product Offerings

7.6.4 Pfizer Rare Hematology Treatment Revenue in Global Market (2017-2022)

7.6.5 Pfizer Key News

7.7 PRA Health Sciences

7.7.1 PRA Health Sciences Corporate Summary

7.7.2 PRA Health Sciences Business Overview

7.7.3 PRA Health Sciences Rare Hematology Treatment Major Product Offerings

7.7.4 PRA Health Sciences Rare Hematology Treatment Revenue in Global Market (2017-2022)

7.7.5 PRA Health Sciences Key News

7.8 Celgene

7.8.1 Celgene Corporate Summary

7.8.2 Celgene Business Overview

7.8.3 Celgene Rare Hematology Treatment Major Product Offerings

7.8.4 Celgene Rare Hematology Treatment Revenue in Global Market (2017-2022)

7.8.5 Celgene Key News

7.9 Alexion Pharma

7.9.1 Alexion Pharma Corporate Summary

7.9.2 Alexion Pharma Business Overview

7.9.3 Alexion Pharma Rare Hematology Treatment Major Product Offerings

7.9.4 Alexion Pharma Rare Hematology Treatment Revenue in Global Market (2017-2022)

7.9.5 Alexion Pharma Key News

7.10 Amgen

7.10.1 Amgen Corporate Summary

7.10.2 Amgen Business Overview

7.10.3 Amgen Rare Hematology Treatment Major Product Offerings

7.10.4 Amgen Rare Hematology Treatment Revenue in Global Market (2017-2022)

7.10.5 Amgen Key News

8 CONCLUSION

9 APPENDIX

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Rare Hematology Treatment Market Opportunities & Trends in Global Market

Table 2. Rare Hematology Treatment Market Drivers in Global Market

Table 3. Rare Hematology Treatment Market Restraints in Global Market

Table 4. Key Players of Rare Hematology Treatment in Global Market

Table 5. Top Rare Hematology Treatment Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Rare Hematology Treatment Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Rare Hematology Treatment Revenue Share by Companies, 2017-2022

Table 8. Global Companies Rare Hematology Treatment Product Type

Table 9. List of Global Tier 1 Rare Hematology Treatment Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Rare Hematology Treatment Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Rare Hematology Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Rare Hematology Treatment Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Rare Hematology Treatment Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Rare Hematology Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Rare Hematology Treatment Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Rare Hematology Treatment Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Rare Hematology Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Rare Hematology Treatment Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Rare Hematology Treatment Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Rare Hematology Treatment Revenue, (US\$, Mn), 2017-2022

Table 21. By Country - North America Rare Hematology Treatment Revenue, (US\$,

Mn), 2023-2028

Table 22. By Country - Europe Rare Hematology Treatment Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Rare Hematology Treatment Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Rare Hematology Treatment Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Rare Hematology Treatment Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Rare Hematology Treatment Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Rare Hematology Treatment Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Rare Hematology Treatment Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Rare Hematology Treatment Revenue, (US\$, Mn), 2023-2028

Table 30. Takeda Corporate Summary

Table 31. Takeda Rare Hematology Treatment Product Offerings

Table 32. Takeda Rare Hematology Treatment Revenue (US\$, Mn), (2017-2022)

Table 33. Biogen Corporate Summary

Table 34. Biogen Rare Hematology Treatment Product Offerings

Table 35. Biogen Rare Hematology Treatment Revenue (US\$, Mn), (2017-2022)

Table 36. Novo Nordisk Corporate Summary

Table 37. Novo Nordisk Rare Hematology Treatment Product Offerings

Table 38. Novo Nordisk Rare Hematology Treatment Revenue (US\$, Mn), (2017-2022)

Table 39. Bayer Corporate Summary

Table 40. Bayer Rare Hematology Treatment Product Offerings

Table 41. Bayer Rare Hematology Treatment Revenue (US\$, Mn), (2017-2022)

Table 42. CSL Behring Corporate Summary

Table 43. CSL Behring Rare Hematology Treatment Product Offerings

Table 44. CSL Behring Rare Hematology Treatment Revenue (US\$, Mn), (2017-2022)

Table 45. Pfizer Corporate Summary

Table 46. Pfizer Rare Hematology Treatment Product Offerings

Table 47. Pfizer Rare Hematology Treatment Revenue (US\$, Mn), (2017-2022)

Table 48. PRA Health Sciences Corporate Summary

Table 49. PRA Health Sciences Rare Hematology Treatment Product Offerings

Table 50. PRA Health Sciences Rare Hematology Treatment Revenue (US\$, Mn), (2017-2022)

Table 51. Celgene Corporate Summary

Table 52. Celgene Rare Hematology Treatment Product Offerings

Table 53. Celgene Rare Hematology Treatment Revenue (US\$, Mn), (2017-2022)

Table 54. Alexion Pharma Corporate Summary

Table 55. Alexion Pharma Rare Hematology Treatment Product Offerings

Table 56. Alexion Pharma Rare Hematology Treatment Revenue (US\$, Mn),
(2017-2022)

Table 57. Amgen Corporate Summary

Table 58. Amgen Rare Hematology Treatment Product Offerings

Table 59. Amgen Rare Hematology Treatment Revenue (US\$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

- Figure 1. Rare Hematology Treatment Segment by Type in 2021
- Figure 2. Rare Hematology Treatment Segment by Application in 2021
- Figure 3. Global Rare Hematology Treatment Market Overview: 2021
- Figure 4. Key Caveats
- Figure 5. Global Rare Hematology Treatment Market Size: 2021 VS 2028 (US\$, Mn)
- Figure 6. Global Rare Hematology Treatment Revenue, 2017-2028 (US\$, Mn)
- Figure 7. The Top 3 and 5 Players Market Share by Rare Hematology Treatment Revenue in 2021
- Figure 8. By Type - Global Rare Hematology Treatment Revenue Market Share, 2017-2028
- Figure 9. By Application - Global Rare Hematology Treatment Revenue Market Share, 2017-2028
- Figure 10. By Region - Global Rare Hematology Treatment Revenue Market Share, 2017-2028
- Figure 11. By Country - North America Rare Hematology Treatment Revenue Market Share, 2017-2028
- Figure 12. US Rare Hematology Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 13. Canada Rare Hematology Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 14. Mexico Rare Hematology Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 15. By Country - Europe Rare Hematology Treatment Revenue Market Share, 2017-2028
- Figure 16. Germany Rare Hematology Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 17. France Rare Hematology Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 18. U.K. Rare Hematology Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 19. Italy Rare Hematology Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 20. Russia Rare Hematology Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 21. Nordic Countries Rare Hematology Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 22. Benelux Rare Hematology Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 23. By Region - Asia Rare Hematology Treatment Revenue Market Share, 2017-2028
- Figure 24. China Rare Hematology Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 25. Japan Rare Hematology Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 26. South Korea Rare Hematology Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 27. Southeast Asia Rare Hematology Treatment Revenue, (US\$, Mn),

2017-2028

Figure 28. India Rare Hematology Treatment Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Rare Hematology Treatment Revenue Market Share, 2017-2028

Figure 30. Brazil Rare Hematology Treatment Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Rare Hematology Treatment Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Rare Hematology Treatment Revenue Market Share, 2017-2028

Figure 33. Turkey Rare Hematology Treatment Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Rare Hematology Treatment Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Rare Hematology Treatment Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Rare Hematology Treatment Revenue, (US\$, Mn), 2017-2028

Figure 37. Takeda Rare Hematology Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Biogen Rare Hematology Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Novo Nordisk Rare Hematology Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Bayer Rare Hematology Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. CSL Behring Rare Hematology Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Pfizer Rare Hematology Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. PRA Health Sciences Rare Hematology Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. Celgene Rare Hematology Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. Alexion Pharma Rare Hematology Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 46. Amgen Rare Hematology Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Rare Hematology Treatment Market - Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/R5176197AA77EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R5176197AA77EN.html>